The Centers for Medicare & Medicaid Services Feb. 20 issued a proposing changes to the Comprehensive Care for Joint Replacement model, which bundles payment to acute care hospitals for hip and knee replacement surgery. Under this model, hospitals in which a joint replacement has taken place are held financially accountable for episode quality and costs. 

Among other proposals, CMS would extend the CJR model for an additional three years, through Dec. 31, 2023, beyond its current five-year timeline. However, this extension would apply only to hospitals in the 34 metropolitan statistical areas in which participation was mandatory. Hospitals participating in the 33 鈥渧oluntary鈥 MSAs, as well as all low-volume and rural hospitals that have elected to participate, will continue to see the model end on Dec. 31, 2020.

The AHA has long been supportive of voluntary participation in alternative payment models as a pathway to potentially improve care coordination and efficiency. As such, the association is disappointed that CMS is not proposing to extend voluntary participation options in the CJR model.
 

Related News Articles

Headline
The AHA June 4 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee in defense of the state鈥檚 340B contract pharmacy law鈥
Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B 鈥渞ebate鈥
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state鈥檚 340B contract pharmacy law鈥
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies鈥 requests to approve their unlawful 340B rebate models. 鈥淭he 340B鈥
Headline
The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state鈥檚 340B contract pharmacy law prohibiting鈥
Headline
The AHA May 1 expressed concerns to the Centers for Medicare & Medicaid Services about the payment process established under the Medicare Drug鈥